Evonik Turns To Net Profit In Q2, But Sales Down; Sees FY25 Adj. EBITDA At Low End Of Outlook Range

Evonik Industries AG reported a Q2 net income of €120 million, a significant turnaround from a prior-year loss, yet its adjusted EBITDA declined to €509 million and sales fell to €3.50 billion, attributed to lower volumes and price erosion. The German specialty chemicals firm also issued a cautious outlook for fiscal 2025, projecting adjusted EBITDA to be at the lower end of its previously guided €2.0 billion to €2.3 billion range.

Analysis

Evonik Industries AG presented a mixed financial picture for its second quarter, swinging to a net income of €120 million from a €5 million loss in the prior-year period. However, this headline profitability masks significant underlying operational weakness. Adjusted EBITDA, a key measure of core performance, declined to €509 million from €578 million year-over-year, while sales fell to €3.50 billion from €3.93 billion. The company explicitly attributes this top-line deterioration to lower sales volumes and an erosion in selling prices, indicating persistent demand headwinds and pricing pressure within the specialty chemicals sector. The most significant signal is the company's cautious forward guidance for fiscal 2025; management now anticipates adjusted EBITDA will land at the lower end of its previously stated €2.0 billion to €2.3 billion range, effectively a soft downgrade that suggests limited confidence in a near-term market recovery.

Key Decisions for Investors

• Investors should adjust their fiscal 2025 models to reflect adjusted EBITDA at the low end of the guided range, near €2.0 billion, given management's explicitly cautious outlook.
• Prioritize the decline in adjusted EBITDA and sales over the headline net profit, as these metrics better reflect the ongoing operational challenges from weak volumes and pricing power.
• A cautious or bearish stance may be warranted until there are tangible signs of a recovery in sales volumes and stabilization in selling prices for the specialty chemicals segment.
• Closely monitor for any commentary on demand trends in key end-markets, as this will be the primary catalyst for any revision to the current negative trajectory.